

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Evusheld for COVID-19 prevention, awake prone positioning, outcomes associated with non-invasive ventilation, high-flow oxygen and CPAP

#### Peer reviewed journals featured:

- A systematic appraisal of good practice statements in COVID-19 guidelines [here](#)
- Randomised controlled trials of:
  - Intramuscular Evusheld (tixagevimab–cilgavimab) for COVID-19 prevention [here](#)
  - Indomethacin for mild and moderate hospitalised COVID-19 patients [here](#)
- A non-randomised controlled trial on awake prone positioning in COVID-19 patients [here](#)
- Observational studies on:
  - Mortality and intubation rate in COVID-19 patients treated with non-invasive ventilation compared with high-flow oxygen or CPAP [here](#)
  - Association of psychiatric disorders with SARS-CoV-2 breakthrough infection [here](#)
  - Surveillance of safety of three doses of COVID-19 mRNA vaccination [here](#)
  - Retinal vascular occlusions after COVID-19 diagnosis [here](#) and commentary [here](#)
  - Vaccine effectiveness in immune-mediated inflammatory diseases [here](#) and commentary [here](#)
  - Occupation, work-related contact and SARS-CoV-2 serological status [here](#)
  - App-based COVID-19 syndrome surveillance and prediction of hospital admissions [here](#)
  - Memory B-cell potency and breadth after a SARS-CoV-2 mRNA boost [here](#)
- Editorials on:
  - Unethical studies of ivermectin for COVID-19 [here](#)
  - Socio-economic conditions and the epidemiology of COVID-19 in Australia [here](#)
- Commentary on
  - Communicating with patients about health-related conspiracy theories [here](#)
  - Universal biosafety standards [here](#)
  - The delivery plan for tackling the COVID-19 backlog of elective care in the UK [here](#)

#### Letters and correspondence discussed:

- Acute upper airway disease in children with the Omicron variant [here](#)
- Changes in injury presentations during the COVID-19 pandemic in the US [here](#)
- Short-term adverse events after third dose of Comirnaty (Pfizer) in adults aged 60+ years [here](#)
- Rates of COVID-19 among unvaccinated adults with prior COVID-19 [here](#)

## Pre-peer review articles featured:

- Systematic reviews on:
  - Antidepressants and severity of COVID-19 [here](#)
  - Methodologies to assess non-pharmaceutical interventions during COVID-19 [here](#)
  - Takotsubo (stress) cardiomyopathy following COVID-19 vaccination [here](#)
- A phase-4 open label trial on immune response to two-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection (Shieldvacc-2 study) [here](#)
- A quality assessment of randomised controlled trials published on COVID-19 [here](#)
- Observational studies on:
  - Coding long COVID using an ICD-10 lens [here](#)
  - Coronavirus infection in neonates and neurodevelopmental outcomes [here](#)
  - Comparison of viral loads in Omicron infections by vaccination status [here](#)
  - Comparison of Comirnaty (Pfizer) booster elicitation of humoral responses by the interval between first two doses [here](#)
  - Wastewater to clinical case (WC) ratio of COVID-19 in urban communities [here](#)
  - Neutralising activity against Omicron BA.2 from mRNA booster vaccination [here](#)
  - Association between community asymptomatic rapid antigen testing and COVID-19 hospital admissions [here](#)
  - Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy [here](#)
  - Accuracy of CDC COVID-19 forecasting models [here](#)
  - Vaccine effectiveness studies:
    - against hospitalisations in children and adolescents during Omicron [here](#)
    - of primary and booster COVID-19 mRNA vaccination against Omicron in people with a prior SARS-CoV-2 Infection [here](#)
    - of a fourth dose of COVID-19 vaccine in long-term care residents [here](#)
    - against severe disease from Omicron BA.1 and BA.2 [here](#)
    - against SARS-CoV-2 infection and COVID-19-related hospitalisation with the Alpha, Delta and Omicron SARS-CoV-2 variants [here](#)
    - Duration of mRNA vaccine effectiveness against severe disease [here](#)

## Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updates [here](#)
- The World Health Organization published updates of its weekly epidemiological report [here](#) and COVID-19 vaccine tracker [here](#)

## News and blogs

- UK approves the whole virus inactivated Valneva vaccine for adults aged under 50 years [here](#)
- Mask mandate is struck down although US cases are rising [here](#)
- Global COVID-19 death toll may be triple the reported deaths [here](#)